A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

• Status: Completed
• Trial end date: 2015-03-17
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Carboxymethylcellulose Sodium; Glycerol; Hyaluronic Acid

Criteria

Inclusion Criteria:

• Use of artificial tears for dry eye in both eyes for at least 3 months

• Use of preservative-free artificial tears at least twice daily for 2 weeks;

Exclusion Criteria:

• Cataract, laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK) surgery in the last 12 months

• Use of punctal plugs or contact lenses in the last month

• Active ocular allergy within last 2 years

• Best corrected visual acuity (BCVA) less than 20/200 in either eye